Short interest for VG Life Sciences gives investors a sense of the degree to which investors are betting on the decline of VG Life Sciences's stock. Short interest data is updated every two weeks.

VG Life Sciences Stock (OTC:VGLS), Short Interest Report

VG Life Sciences Inc. is a holding company restructuring its business to focus on real estate investment and acquisitions, development, and value-added development, resource mining and processing.

News

Guidance

Financing

Management

Global

VGLS

VG Life Sciences Provides Update on Phase I Advanced Stage Solid Tumor Cancer Study

VG LIFE SCIENCES INC by VG Life Sciences Inc.

VG Life Sciences Inc

VG Life Sciences, (OTC: <a class="ticker" href="/stock/vgls#OTC">VGLS</a>) announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
	The study reported two clinical responses in cohort 3 with disease stabilization in a patient with metastatic ovarian cancer for 4 months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. The final patient in cohort #3 has stage IV (metastatic) adenocarcinoma of the lung. The four (4) separate lung lesions have all regressed about 20%.
	This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health Sciences Center at San Antonio. The primary investigator is medical oncologist Tyler Curiel, M.D., MPH and is based on the research of Dr. M. Karen Newell-Rogers, PhD VG Life Sciences, Inc.'s Chief Scientific Advisor.
	The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.
 <a href="http://www.benzinga.com/pressreleases/14/03/g4390970/vg-life-sciences-inc-s-reports-on-clinical-outcomes-in-phase-i-cancer-s">See full press release</a>

VG Life Sciences Reports on Clinical Outcomes in Phase I Advanced Sstage Solid Tumor Study

VG Life Sciences (OTC: <a class="ticker" href="/stock/vgls#OTC">VGLS</a>) announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health Sciences Center at San Antonio . The primary investigator is medical oncologist Tyler Curiel, M.D., MPH and is based on the research of Dr. M. Karen Newell-Rogers, PhD VG Life Sciences, Inc.'s Chief Scientific Advisor. 
The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals. VG Life Sciences, Inc. holds the use patent for this combination treatment.
 <a href="http://www.benzinga.com/pressreleases/13/12/n4153471/vg-life-sciences-inc-update-on-phase-i-cancer-study">See full press release</a>